Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 257

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic...

Book Review: Alexander Shulgin’s The Nature of Drugs

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and...

Awakn Life Sciences to Commence Trading on the NEO Exchange under...

MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural...

Filament Health Corp. Announces Approval for Listing on the Neo Exchange

PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including...

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Load more

EDITOR PICKS

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit...

Quarterly Psychedelics Briefing: Q2 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©